A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Leucine/metformin/sildenafil (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Acronyms TRIPLN
- Sponsors NuSirt Biopharma
- 12 Sep 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 27 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 May 2017.